Brownstein Hyatt Farber Schreck is pleased to announce Matthew Nyberg’s appointment to the board of directors for the Colorado Cancer Research Program.
Nyberg, a shareholder in the firm’s Denver office, will apply his extensive familiarity with business from his practice as a corporate attorney to his position on the board. His appointment is for two years.
The Colorado Cancer Research Program is a non-profit organization founded in 1988 to advance oncology research. More than 100 physicians, 19 hospital and 30 physical clinics participate in the program across Colorado. The program supports clinical trials in supportive care/cancer control, diagnostic/screening, treatment and prevention. For more information, visit http://www.co-cancerresearch.org.